Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database

Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database

Abstract Background Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS). Methods...

Full description

Bibliographic Details
Main Authors: Isabelle Koné-Paut, Sophie Georgin-Lavialle, Alexandre Belot, Magali Jover, Mathilde Pouriel, Laure Lacoin, Pascal Pillet, Véronique Hentgen
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Arthritis Research & Therapy
Subjects:
Canakinumab
FMF
MKD
TRAPS
Treatment patterns
Safety
Online Access:https://doi.org/10.1186/s13075-024-03316-7

Internet

https://doi.org/10.1186/s13075-024-03316-7

Similar Items